-
Information-Publications
-
Cytotoxic CD161− CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosusDetails
-
SUMOylation of the ubiquitin ligase component KEAP1 at K39 upregulates NRF2 and its target function in lung cancer cell proliferationDetails
-
Lysophosphatidylcholine acyltransferase 3 (LPCAT3) mediates palmitate-induced inflammation in macrophages of large yellow croaker (Larimichthys crocea)Details
-
Design of prime-editing guide RNAs with deep transfer learningDetails
-
A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modelingDetails
-
A Novel Double-Stranded DNA Deaminase-Based and Transcriptional Activator-Assisted Nuclear and Mitochondrial Cytosine Base Editors with Expanded TargetDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands